Table 3.
Measurement of TNF-α, IL-6, and IL-10 cytokines in macrophages infected with MAP or treated with LPS following treatment with RHB-104 and its major components.
| Treatment | Antibiotic Concentration (µg/mL) | TNF-α ± SD (pg/mL) |
IL-6 ± SD (pg/mL) |
IL-10 ± SD (pg/mL) |
|---|---|---|---|---|
| MAP Control | - | 191.2 ± 8.6 | 201.8 ± 11.7 | 61.9 ± 9.8 |
| LPS Control | - | 217.4 ± 5.1 | 224.3 ± 9.6 | 52.2 ± 7.4 |
| No Treatment | - | 75.7 ± 6.5 | 82.9 ± 5.1 | 100.4 ± 6.5 |
| MAP + RHB-104 | 0.50 | 175.3 ± 8.4 | 182.2 ± 8.1 | 79.2 ± 2.9 |
| 1.00 | 123.7 ± 6.7 * | 139.4 ± 3.2 * | 88.6 ± 3.5 * | |
| 2.00 | 95.8 ± 1.8 * | 117.5 ± 2.5 * | 95.1 ± 5.8 * | |
| MAP + CLA | 0.32 | 184.7 ± 3.6 | 191.5 ± 8.3 | 68.3 ± 3.1 |
| 0.63 | 165.8 ± 5.1 | 173.6 ± 3.1 | 75.4 ± 2.7 | |
| 1.26 | 146.1 ± 6.2 * | 153.2 ± 4.6 * | 80.3 ± 8.7 | |
| MAP + RIF | 0.15 | 187.2 ± 5.3 | 197.3 ± 7.2 | 63.6 ± 4.1 |
| 0.30 | 179.1 ± 1.9 | 184.9 ± 5.9 | 70.2 ± 2.1 | |
| 0.60 | 166.4 ± 8.3 | 172.8 ± 3.9 | 77.3 ± 3.4 | |
| LPS + RHB-104 | 0.5 | 179.3 ± 2.0 | 182.6 ± 5.1 | 76.4 ± 6.3 |
| 1.0 | 139.7 ± 4.7 * | 151.1 ± 2.5 * | 84.3 ± 6.9 * | |
| 2.0 | 110.9 ± 4.0 * | 137.2 ± 2.7 * | 91.1 ± 5.2 * | |
| LPS + CLA | 0.32 | 185.8 ± 1.6 | 193.3 ± 4.4 | 61.2 ± 4.2 |
| 0.63 | 162.4 ± 6.2 | 174.8 ± 3.6 | 69.7 ± 7.8 | |
| 1.26 | 158.2 ± 7.3 * | 169.7 ± 1.1 * | 71.9 ± 6.9 | |
| LPS + RIF | 0.15 | 188.3 ± 3.1 | 206.8 ± 8.0 | 54.6 ± 2.3 |
| 0.30 | 179.7 ± 8.9 | 192.4 ± 1.3 | 62.4 ± 7.2 | |
| 0.60 | 166.1 ± 5.6 | 182.1 ± 1.6 | 67.5 ± 4.9 |
* p < 0.05.